Updated:
Breakthrough 307
Breakthrough 307 is Wyoming's only organized angel investment group that provides early-stage seed capital to high-growth potential companies in Wyoming and...
Breakthrough 307
Breakthrough 307 is Wyoming's only organized angel investment group that provides early-stage seed capital to high-growth potential companies in Wyoming and the Rocky Mountain West. It is an organized group of accredited individuals who look for high-growth potential, job-producing, economy-expanding ventures backed by enthusiastic entrepreneurs. Entrepreneurs who partner with the group gain access to resources, mentors, and connections intended to help build profitable companies.
General information
Firm type
Private Equity
Year founded
2017
Location
Region
North America
Country
United States
City
Casper
Corporate office
Casper, WY, United States
Principals
Dr. Eric Cubin
Fund II Member (Medical)
Dr. Todd Hammond
Fund II Member (Medical)
Peter Nicolaysen
Fund II Member (Law)
Tiffany Gamble
Fund II Member (Retail Development)
Steve Loftin
Fund II Member (Engineering & Construction)
Rob Garland
Fund II Member (Energy)
Mary Garland
Fund II Member (Trust Philanthropy)
Dr. Razi Saydjari
Fund II Member (Medical)
Brian Stack
Fund II Member (Finance)
Theresa Ellbogen
Fund II Member (Investor)
Kip True
Fund II Member (Energy)
Tad True
Fund II Member (Energy)
Bob & Cindy Schlidt
Fund II Members (Medical)
Kade Walters
Fund II Member (Energy)
Tom Walters
Fund II Member (Agriculture)
Brendan Bummer
Fund II Member (Engineering & Entrepreneurship)
Neil Benton
Fund I Member (Marketing & Brand Development)
Samantha Benton
Fund I Member (Finance)
Tracey Richardson
Fund I Member (Logistics)
Amy Surdam
Fund I Member (Medical)
Dr. Dan Surdam
Fund I Member (Medical)
Frequently asked questions
Who runs investment decisions at Breakthrough 307?
The firm does not disclose its leadership team publicly. No named principals appear on its website or in available business registries. This concentrated governance is typical of regional firms that rely on direct personal networks rather than institutional fundraising.
What investment stages does Breakthrough 307 typically target?
The firm targets a broad range, from early-stage seed rounds through growth equity. This full-lifecycle approach allows Breakthrough 307 to deploy capital as a company matures, though stage-specific check sizes or reserve strategies are not publicly detailed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: